Impact of immune-related adverse events on response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer: a single-institution retrospective study

Key Points

• To evaluate how immune-related adverse events affect treatment response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer patients.
• Conducted a retrospective study at a single institution
• Analyzed the impacts of immune-related adverse events on treatment outcomes
• Examined variations in response based on age and race
• Immune-related adverse events may indicate better treatment responses
• Racial and age differences in treatment response were observed
• Findings underscore the need for inclusion of diverse patient populations in immunotherapy research